Stock analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR – Get Rating) in a report issued on Sunday. The firm set a "sell" rating on the stock.

InspireMD Price Performance

NSPR opened at $1.71 on Friday. InspireMD has a fifty-two week low of $1.68 and a fifty-two week high of $4.68. The firm's fifty day moving average price is $1.85 and its two-hundred day moving average price is $2.25. The company has a market capitalization of $14.22 million, a P/E ratio of -0.77 and a beta of 1.20.

InspireMD (NYSE:NSPR – Get Rating) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.59) earnings per share for the quarter. InspireMD had a negative return on equity of 54.85% and a negative net margin of 334.66%. The business had revenue of $1.53 million for the quarter.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.

Recommended Stories

• Get a free copy of the StockNews.com research report on InspireMD (NSPR)
• 3 Banks Worth Considering For Q4
• Stock Market: 3 Islands Of Strength In A Sea Of Red
• No One Told These 3 Stocks It's a Down Week
• Is There a Cure for What is Ailing Teladoc Stock?
• MarketBeat: Week in Review 9/12 – 9/16

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.